Department of Psychiatry, Radboud University Medical Center, 966, Postbus 9101, 6500 HB, Nijmegen, The Netherlands.
Department of Medical Psychology, Radboud University Medical Center, Nijmegen, The Netherlands.
BMC Psychol. 2023 Jan 25;11(1):21. doi: 10.1186/s40359-023-01052-2.
One third of cancer patients and survivors experience psychological distress. Previous studies have shown that online mindfulness-based cognitive therapy (eMBCT) supports cancer patients and survivors in managing distress. Lack of peer support and asynchronicity during online interventions have been reported as barriers for treatment adherence and can result in higher drop-out rates. Considering this, two new formats of eMBCT were created. The primary objective of the Buddy trial is to evaluate the (cost) effectiveness of blended and unguided eMBCT versus care as usual (CAU) on psychological distress among cancer patients and survivors. Secondary objectives include evaluating effects on other psychological outcomes and investigating working mechanisms and treatment effect moderators.
The Buddy trial is a parallel three-armed randomized controlled trial. Participants will be randomly assigned to blended therapist-assisted eMBCT, unguided individual eMBCT or CAU. Eligible participants will be Dutch-speaking adult cancer patients or survivors with access to internet. The primary outcome will be psychological distress scores as assessed by the Hospital Anxiety and Depression scale immediately post-treatment. Secondary outcome measures include fear of cancer recurrence (FCRI), fatigue (CIS-F), rumination (RRQ), mindfulness skills (FFMQ), decentering (EQ), self-compassion (SCS-SF), positive mental health (MHCSF), health related quality of life (EQ-5D), and costs associated with psychiatric illness (TiC-P). Outcome measures will be evaluated at baseline, mid-treatment, immediately post-treatment, and three-, six-, and nine-months follow-up. Possible mediators, such as engagement with interventions (TWEETS), and moderators will be also analyzed.
There is room to improve eMBCT for cancer patients prior to implementation to ensure adherence and scalability. Blended and unguided eMBCT may reduce psychological distress and improve quality of life and be easily accessible to cancer patients and survivors. Trial registration clinicaltrials.gov, NCT05336916, registered on April 20th, 2022. https://clinicaltrials.gov/ct2/show/NCT05336916 .
三分之一的癌症患者和幸存者会经历心理困扰。之前的研究表明,在线正念认知疗法(eMBCT)可以帮助癌症患者和幸存者应对困扰。在线干预中缺乏同伴支持和异步性被报道为治疗依从性的障碍,可能导致更高的脱落率。考虑到这一点,创建了两种新的 eMBCT 格式。“伙伴”试验的主要目的是评估混合和非指导的 eMBCT 与常规护理(CAU)对癌症患者和幸存者心理困扰的(成本)有效性。次要目标包括评估对其他心理结果的影响,并研究工作机制和治疗效果的调节因素。
“伙伴”试验是一项平行的三臂随机对照试验。参与者将被随机分配到混合治疗师辅助的 eMBCT、非指导的个体 eMBCT 或 CAU。合格的参与者将是荷兰语母语的成年癌症患者或幸存者,并且能够上网。主要结局将是治疗后立即通过医院焦虑和抑郁量表评估的心理困扰评分。次要结局指标包括癌症复发恐惧(FCRI)、疲劳(CIS-F)、反刍(RRQ)、正念技能(FFMQ)、去中心化(EQ)、自我同情(SCS-SF)、积极心理健康(MHCSF)、健康相关生活质量(EQ-5D)和与精神疾病相关的成本(TiC-P)。在基线、治疗中期、治疗后立即以及 3、6 和 9 个月随访时评估结局测量。还将分析可能的中介因素,如对干预的参与(TWEETS)和调节因素。
在实施之前,有必要改进 eMBCT 以提高癌症患者的依从性和可扩展性。混合和非指导的 eMBCT 可能会减轻心理困扰,提高生活质量,并且易于癌症患者和幸存者获得。试验注册临床Trials.gov,NCT05336916,于 2022 年 4 月 20 日注册。https://clinicaltrials.gov/ct2/show/NCT05336916。